CC-92480, Tazemetostat, BMS-986158, Trametinib — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-10-12 in 4mo
ESTIMATED |
READOUT
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-98634
Phase 1/2 · Multiple Myeloma |
BMY BRISTOL MYERS SQUIBB CO | CC-92480, Tazemetostat, BMS-986158, Tram |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|